

### **Synonym**

PDCD1,PD1,CD279,SLEB2

## Source

Rhesus macaque PD-1, His Tag (PD1-R52H3) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # <u>B0LAJ2-1</u>). Predicted N-terminus: Leu 25

## **Molecular Characterization**

PD-1(Leu 25 - Gln 167) B0LAJ2-1

Poly-his

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 17.9 kDa. The protein migrates as 33-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

#### **Endotoxin**

Less than 1.0 EU per µg by the LAL method.

#### **Purity**

>90% as determined by SDS-PAGE.

>95% as determined by SEC-MALS.

## **Formulation**

Lyophilized from  $0.22~\mu m$  filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

#### Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

## Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.


# SDS-PAGE



Rhesus macaque PD-1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

## **Bioactivity-ELISA**


# SEC-MALS




The purity of Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) was more than 95% and the molecular weight of this protein is around 25-35 kDa verified by SEC-MALS.

Report






Immobilized Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) at 2  $\mu$ g/mL (100  $\mu$ L/well) can bind nivolumab with a linear range of 0.1-3 ng/mL (QC tested).



Immobilized Biotinylated Human PD-L1, Fc,Avitag (Cat. No. <u>PDL-H82F2</u>) at 1  $\mu$ g/mL (100  $\mu$ L/well) on streptavidin (Cat. No. <u>STN-N5116</u>) precoated (0.5  $\mu$ g/well) plate can bind Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) with a linear range of 0.078-0.625  $\mu$ g/mL (Routinely tested).



Immobilized Biotinylated Human PD-L2, Fc, Avitag (Cat. No. <u>PD2-H82F6</u>) at 1  $\mu$ g/mL (100  $\mu$ L/well) on streptavidin (Cat. No. <u>STN-N5116</u>) precoated (0.5  $\mu$ g/well) plate can bind Rhesus macaque PD-1, His Tag (Cat. No. PD1-R52H3) with a linear range of 0.01-0.313  $\mu$ g/mL (Routinely tested).

## Background

Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

## References

Please contact us via <u>TechSupport@acrobiosystems.com</u> if you have any question on this product.